Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.65 |
---|---|
High | 10.25 |
Low | 9.53 |
Bid | 9.70 |
Offer | 9.98 |
Previous close | 9.67 |
Average volume | 336.48k |
---|---|
Shares outstanding | 55.33m |
Free float | 44.77m |
P/E (TTM) | -- |
Market cap | 552.73m USD |
EPS (TTM) | -1.95 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
- Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
- Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
- Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
- Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
- Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
- Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
- Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
- Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
More ▼